Literature DB >> 15293349

Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice.

Chunni Zhu1, Yun Zhang, Yu-Feng Zhang, Jian Yi Li, Ruben J Boado, William M Pardridge.   

Abstract

BACKGROUND: The tissue-specific expression of an exogenous gene, under the influence of a tissue-specific promoter, has been examined in the past with pro-nuclear injections of the transgene and the development of transgenic mouse models. 'Adult transgenics' is possible with the acute expression of an exogenous gene that is administered to adult animals, providing the transgene can be effectively delivered to distant sites following an intravenous administration.
METHODS: The organ specificity of exogenous gene expression in adult mice was examined with a bacterial beta-galactosidase (LacZ) expression plasmid under the influence of the bovine rhodopsin gene promoter. The 8-kb plasmid DNA was delivered to organs following an intravenous administration with the pegylated immunoliposome (PIL) non-viral gene transfer technology. The PIL carrying the gene was targeted to organs with the rat 8D3 monoclonal antibody (MAb) to the mouse transferrin receptor (TfR).
RESULTS: The rhodopsin/beta-galactosidase gene was expressed widely in both the eye and the brain of adult mice, but was not expressed in peripheral tissues, including liver, spleen, lung, or heart. Ocular expression included the retinal-pigmented epithelium, the iris, and ciliary body, and brain expression was observed in neuronal structures throughout the cerebrum and cerebellum.
CONCLUSIONS: The expression of trans-genes in adult animals is possible with the PIL non-viral gene transfer method. The opsin promoter enables tissue-specific gene expression in the eye, as well as the brain of adult mice, whereas gene expression in peripheral tissues, such as liver or spleen, is not observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15293349     DOI: 10.1002/jgm.575

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  8 in total

Review 1.  Nanoparticulate systems for drug delivery and targeting to the central nervous system.

Authors:  Emanuela Fabiola Craparo; Maria Luisa Bondì; Giovanna Pitarresi; Gennara Cavallaro
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

Review 2.  shRNA and siRNA delivery to the brain.

Authors:  William M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

3.  Efficient down-regulation of glia maturation factor expression in mouse brain and spinal cord.

Authors:  Smita Zaheer; Yanghong Wu; Xi Yang; Ramasamy Thangavel; Shailendra K Sahu; Asgar Zaheer
Journal:  Neurochem Res       Date:  2012-03-25       Impact factor: 3.996

Review 4.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

5.  Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy.

Authors:  Yun Zhang; William M Pardridge
Journal:  Pharm Res       Date:  2008-12-23       Impact factor: 4.200

Review 6.  Drug targeting to the brain.

Authors:  William M Pardridge
Journal:  Pharm Res       Date:  2007-06-07       Impact factor: 4.200

7.  Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV.

Authors:  S R Singh; H E Grossniklaus; S J Kang; H F Edelhauser; B K Ambati; U B Kompella
Journal:  Gene Ther       Date:  2009-02-05       Impact factor: 5.250

Review 8.  Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.

Authors:  William M Pardridge
Journal:  Front Med Technol       Date:  2020-11-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.